Abbott Laboratories ABT Abbott Reports Strong Second Quarter Results
Abbott Laboratories (ABT) - Abbott Reports Strong Second Quarter Results
RNS Number : 9553H
Abbott Laboratories
18 July 2012
Abbott Reports Strong Second Quarter Results
- Second-Quarter Ongoing EPS of $1.23, an Increase of Nearly 10 Percent and
Exceeding the Company's Quarterly Guidance Range; GAAP EPS of $1.08 -
- Confirms Full-Year 2012 Ongoing EPS Guidance Range -
- Significant Gross Margin Improvement -
- On Track to Separate into Two Leading Health Care Companies at Year End -
ABBOTT PARK, Ill., July 18, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today
announced financial results for the second quarter ended June 30, 2012.
· Diluted earnings per share, excluding specified items, were $1.23,
reflecting 9.8 percent growth, exceeding Abbott's guidance range. Diluted
earnings per share under Generally Accepted Accounting Principles (GAAP) were
$1.08, including specified items.
· Excluding foreign exchange, worldwide sales increased 6.7 percent.
Reported sales increased 2.0 percent, including an unfavorable 4.7 percent
effect of foreign exchange.
· Second-quarter results included an adjusted gross margin ratio of 63.3
percent, an increase of 310 basis points over 2011, driven by improved
efficiencies across a number of operating divisions, favorable product mix and
the effect of foreign exchange. The gross margin ratio under GAAP was 62.9
percent.
· Abbott is confirming its ongoing earnings-per-share guidance for 2012
of $5.00 to $5.10, reflecting another year of expected strong performance.
Including specified items, projected earnings per share under GAAP would be
$4.29 to $4.39 for the full-year 2012.
"Abbott continues to deliver strong results as we remain on track to separate
into two leading health care companies," said Miles D. White, chairman and
chief executive officer, Abbott. "During the second quarter, we launched and
advanced numerous projects in our promising, broad-based pipeline and achieved
key milestones in the separation process."
The following is a summary of second-quarter 2012 sales by major business
category.
% Change vs. 2Q11
Sales ($ in
millions) Int'l Total
U.S. Int'l Total U.S. Operational Reported Operational Reported
Total
Sales 4,178 5,629 9,807 6.1 7.0 (0.9) 6.7 2.0
Proprietary
Pharmaceuticals 2,485 1,895 4,380 7.9 10.9 1.2 9.3 4.9
Nutritionals 741 843 1,584 13.1 4.5 1.0 8.3 6.3
Established
Pharmaceuticals -- 1,246 1,246 n/a 3.8 (6.0) 3.8 (6.0)
Core Laboratory
Diagnostics 175 709 884 15.3 7.2 0.7 8.6 3.3
Molecular Diagnostics 48 58 106 7.3 4.1 (3.8) 5.5 1.0
Point of Care Diagnostics 70 18 88 16.9 4.7 1.3 14.3 13.5
Vascular(a) 307 459 766 (22.2)a 11.1 4.3 (4.7)a (8.3)a
Diabetes Care 144 186 330 8.6 (0.3) (7.7) 3.3 (1.2)
Medical Optics 103 180 283 1.0 1.0 (3.9) 1.0 (2.1)
Other Sales 105 35 140 10.9 9.8 2.4 10.6 8.6
The following is a summary of six-month 2012 sales by major business category.
% Change vs. 1H11
Sales ($ in millions) Int'l Total
U.S. Int'l Total U.S. Operational Reported Operational Reported
Total
Sales 7,901 11,363 19,264 6.0 6.5 1.4 6.3 3.3
Proprietary
Pharmaceuticals 4,538 3,914 8,452 7.3 10.6 4.5 8.9 6.0
Nutritionals 1,448 1,702 3,150 12.0 7.1 5.0 9.3 8.1
Established
Pharmaceuticals -- 2,503 2,503 n/a 2.8 (3.9) 2.8 (3.9)
Core Laboratory
Diagnostics 349 1,388 1,737 14.1 6.1 1.9 7.6 4.1
Molecular Diagnostics 95 116 211 5.2 7.6 1.9 6.6 3.4
Point of Care Diagnostics 134 38 172 16.8 15.9 14.3 16.7 16.3
Vascular(b) 649 920 1,569 (17.2)b 6.5 2.7 (4.6)b (6.6)b
Diabetes Care 283 365 648 8.0 (3.6) (8.2) 1.0 (1.8)
Medical Optics 203 352 555 1.3 1.6 (1.3) 1.4 (0.4)
Other Sales 202 65 267 14.1 (4.3) (8.5) 8.8 7.6
Notes: 1) See "Consolidated Statement of Earnings" for more information.
2) "Operational" growth reflects percentage change over the prior year
excluding the impact of exchange rates.
(a) In the second quarter, excluding the expected decline of certain royalty
and supply arrangement revenues (including Promus), worldwide
operational sales increased 4.6 percent, worldwide reported sales
increased 0.4 percent, and U.S. Vascular sales decreased 6.0 percent.
(b) In the first half, excluding the expected decline of certain royalty and
supply arrangement revenues (including Promus), worldwide operational
sales increased 4.5 percent, worldwide reported sales increased 2.1
percent, and U.S. Vascular sales increased 0.7 percent.
n/a = Not applicable
The following is a summary of second-quarter 2012 sales for select products.
% Change vs. 2Q11
Sales ($ in
millions) Int'l Total
U.S. Int'l Total U.S. Operational Reported Operational Reported
HUMIRA 1,056 1,270 2,326 27.9 19.5 8.4 23.0 16.5
TRILIPIX/TriCor
(fenofibrate) 311 77 388 (5.2) (2.3) (12.2) (4.5) (6.6)
AndroGel 276 8 284 26.1 (5.7) (10.2) 24.9 24.7
Kaletra 70 205 275 (12.5) (13.4) (20.1) (13.2) (18.3)
Lupron 140 60 200 3.9 (7.0) (14.1) 0.2 (2.2)
Niaspan 211 -- 211 (14.7) n/a n/a (14.7) (14.7)
Synthroid 122 27 149 (13.0) 19.8 6.5 (8.0) (10.0)
Creon 88 74 162 12.1 16.9 4.8 14.4 8.7
Pediatric
Nutritionals 374 489 863 25.3 4.5 1.8 12.5 10.8
Adult
Nutritionals 362 354 716 3.0 4.3 (0.3) 3.7 1.4
Xience
Drug-Eluting
Stents 140 260 400 (2.6) 10.4 4.7 5.6 2.0
Other Coronary
Products(c) 49 98 147 (5.6) (0.6) (7.3) (2.3) (6.8)
Endovascular(d) 60 55 115 (4.6) 9.7 0.8 2.0 (2.1)
The following is a summary of six-month 2012 sales for select products.
% Change vs. 1H11
Sales ($ in
millions) Int'l Total
U.S. Int'l Total U.S. Operational Reported Operational Reported
HUMIRA 1,828 2,431 4,259 25.6 18.5 11.1 21.3 16.9
TRILIPIX/TriCor
(fenofibrate) 565 152 717 (8.4) (2.1) (8.9) (7.1) (8.5)
AndroGel 508 16 524 24.9 9.8 6.1 24.3 24.2
Kaletra 125 371 496 (13.6) (10.6) (15.8) (11.3) (15.2)
Lupron 282 118 400 10.6 (7.7) (12.3) 4.2 2.6
Niaspan 402 -- 402 (15.0) n/a n/a (15.0) (15.0)
Synthroid 252 52 304 (2.3) 13.5 4.5 0.3 (1.2)
Creon 156 152 308 9.2 17.3 9.4 13.2 9.3
Pediatric
Nutritionals 731 992 1,723 20.2 8.6 7.1 13.2 12.3
Adult
Nutritionals 710 710 1,420 5.0 5.1 2.2 5.1 3.6
Xience
Drug-Eluting
Stents 290 514 804 7.6 5.6 2.6 6.2 4.3
Other Coronary
Products(c) 101 201 302 (1.9) 2.2 (2.0) 0.8 (2.0)
Endovascular(d) 122 106 228 (0.2) 8.6 3.0 3.8 1.2
Notes: 1) See "Consolidated Statement of Earnings" for more information.
2) "Operational" growth reflects percentage change over the prior year
excluding the impact of exchange rates.
(c) Includes guide wires, balloon catheters and other coronary products.
(d) Includes vessel closure, carotid stents and other peripheral products.
n/a = Not applicable
Business Highlights
Received Approval for Next-Generation XIENCE PRIME Drug Eluting Stent in Japan
Announced approval in Japan for the next-generation XIENCE PRIME^™ drug
eluting stent for the treatment of coronary artery disease. XIENCE PRIME
features an enhanced delivery system designed for greater flexibility, ideal
radial strength, excellent longitudinal strength and more accurate placement.
Received Positive Opinion for HUMIRA in Axial Spondyloarthritis
Received Positive Opinion in Europe for HUMIRA^® in patients with
non-radiographic axial spondyloarthritis (axSpA). Also presented new data
including Phase 3 results in axSpA, Phase 3 results in peripheral
spondyloarthritis, and 10-year data in patients with long-standing rheumatoid
arthritis.
Announced Opening of First Nutrition R&D Center in India
Established a nutrition R&D center in India in collaboration with Syngene,
India's leading contract research organization. The center will focus on the
development of science-based, affordable nutrition products and enable the
expansion of Abbott's nutrition product portfolio in India.
Acquired Investigational Compound for Prevention of Acute Kidney Injury
Enhanced Abbott's pipeline in renal care with the acquisition of AP214 from
Action Pharma A/S. AP214 is in development to prevent acute kidney injury
associated with major cardiac surgery in patients at increased risk and has
further potential in adjacent indications. AP214 is now known as ABT-719.
Launched Three New Medical Optics Technologies
Received U.S. approval for iFS Advanced Femtosecond Laser in cataract surgery
and Healon EndoCoat OVD for use as a surgical aid in cataract extraction and
intraocular lens implantation. Additionally, Abbott launched in Europe and
Japan the iDesign Advanced WaveScan Studio aberrometer for mapping and
analyzing corneal aberrations in the eye.
Initiated Phase 3 Study of Elagolix in Patients with Endometriosis
Announced the initiation of a pivotal Phase 3 clinical trial designed to
evaluate the safety and efficacy of elagolix in female patients with
endometriosis. Elagolix is an oral gonadotropin-releasing hormone (GnRH)
antagonist, and is also being studied for the treatment of uterine fibroids.
Received XIENCE Indication in Europe for Three-Month Dual Anti-Platelet
Therapy
Announced that XIENCE PRIME and XIENCE V^® have received CE Mark in Europe for
the use of dual anti-platelet therapy (DAPT) for at least three months after
stent implantation in patients with coronary artery disease. This is the
shortest duration of DAPT for any major drug eluting stent in Europe.
Introduced New Nutritional Products in the United States
Announced the launch of several new nutritional products, including PediaSure
SideKicks® Clear for picky eaters, Ensure Clear™ fruit-flavored beverages,
ZonePerfect Perfectly Simple™ limited-ingredient nutrition bars, and a new
line of EAS® performance nutrition products for athletes.
Presented Strong Phase 2 Results from Abbott's Advancing Hepatitis C Program
Presented clinical trial results from two interferon-free, Phase 2 studies for
the treatment of hepatitis C, PILOT and CO-PILOT. Additional data from
Abbott's advancing hepatitis C program will be presented later this year at
the American Association for the Study of Liver Diseases (AASLD) meeting.
Introduced New Laboratory Solutions and Diagnostic Assays
Launched key laboratory solutions, including OneLab, a novel, integrated
Web-based software platform to help customers manage laboratory information,
as well as important diagnostic tests in the areas of metabolics and
infectious disease.
Abbott confirms ongoing earnings-per-share outlook for 2012
Abbott is confirming its ongoing earnings-per-share guidance for the full-year
2012 of $5.00 to $5.10, reflecting another year of expected strong
performance.
Abbott forecasts specified items for the full-year 2012 of approximately $0.71
per share, primarily associated with in-process R&D, separation costs,
acquisition integration and cost-reduction initiatives. Including these
specified items, projected earnings per share under Generally Accepted
Accounting Principles (GAAP) would be $4.29 to $4.39 for the full-year 2012.
Our full-year forecast of specified items has increased from our previous
guidance as it now includes expected 2012 one-time separation costs related to
the planned separation of Abbott into two companies. The forecast of specified
items does not include bond refinancing costs related to the planned
separation, which will be quantified at a later date.
Abbott declares 354th quarterly dividend
On June 8, 2012, the board of directors of Abbott declared the company's
quarterly common dividend of 51 cents per share. The cash dividend is payable
Aug. 15, 2012, to shareholders of record at the close of business on July 13,
2012. This marks the 354th consecutive dividend paid by Abbott since 1924.
Abbott is a member of the S&P 500 Dividend Aristocrats Index, which tracks
companies that have annually increased their dividends for 25 consecutive
years.
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery,
development, manufacture and marketing of pharmaceuticals and medical
products, including nutritionals, devices and diagnostics. The company employs
approximately 91,000 people and markets its products in more than 130
countries.
Abbott's news releases and other information are available on the company's
Web site at www.abbott.com. Abbott will webcast its live second-quarter
earnings conference call through its Investor Relations Web site at
www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of
the call will be available after 11 a.m. Central time.
- Private Securities Litigation Reform Act of 1995 -
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995, including
the planned separation of the research-based pharmaceutical company from the
diversified medical products company and the expected financial results of the
two companies after the separation. Abbott cautions that these forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially from those indicated in the forward-looking
statements. Economic, competitive, governmental, technological and other
factors that may affect Abbott's operations are discussed in Item 1A, "Risk
Factors," to our Annual Report on Securities and Exchange Commission Form 10-K
for the year ended Dec. 31, 2011, and are incorporated by reference. Abbott
undertakes no obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments.
Abbott Laboratories and Subsidiaries
Consolidated Statement of Earnings
Second Quarter Ended June 30, 2012 and 2011
(in millions, except per share data)
(unaudited)
%
2012 2011 Change
$ $
Net Sales 9,807 9,616 2.0
Cost of products sold 3,637 3,870 (6.0)
Research and development 1,011 1,038 (2.6)
Acquired in-process and collaborations research and
development 110 173 n/m
Selling, general and
administrative 2,945 2,762 6.6
Total Operating Cost and Expenses 7,703 7,843 (1.8)
Operating earnings 2,104 1,773 18.7
Net interest expense 107 115 (7.4)
Net foreign exchange (gain) loss (14) (11) n/m
Other (income) expense, net 8 (6) n/m
Earnings before taxes 2,003 1,675 19.6
Taxes on earnings 278 (268) n/m 1)
$ $
Net Earnings 1,725 1,943 (11.2)
$ $
Net Earnings Excluding Specified Items, as described below 1,966 1,768 11.2 2)
$ $
Diluted Earnings per Common Share 1.08 1.23 (12.2)
Diluted Earnings Per Common Share, Excluding Specified Items,
$ $
as described below 1.23 1.12 9.8 2)
Average Number of Common Shares Outstanding Plus Dilutive
Common Stock Options and Awards 1,589 1,566
1) 2011 Taxes on earnings
includes a favorable
adjustment to tax
expense of $519
million, or $0.33 per
share, as a result of
the resolution of
various prior years'
international and U.S.
tax positions. This
favorable item is
classified as a
specified item and
excluded from ongoing
results, as discussed
below.
2) 2012 Net Earnings
Excluding Specified
Items excludes
after-tax charges of
$64 million, or $0.04
per share, related to
expenses associated
with the separation
transaction, $71
million, or $0.05 per
share, for acquired
in-process research and
development related to
the Action Pharma asset
acquisition, and $106
million, or $0.06 per
share, related
primarily to
restructuring and
integration charges.
2011 Net Earnings
Excluding Specified
Items excludes
after-tax charges of
$60 million, or $0.04
per share, associated
with the acquisition of
Solvay Pharmaceuticals,
$35 million, or $0.02
per share, for cost
reduction initiatives
and other, $76 million,
or $0.05 per share, for
the impairment of an
R&D intangible asset,
and $173 million, or
$0.11 per share,
relating to acquired
in-process research and
development related to
the Reata and Biotest
collaborations. These
items were offset by a
favorable adjustment
from the resolution of
prior years'
international and U.S.
tax positions for $519
million, or $0.33 per
share.
NOTE: See attached questions and answers section for further explanation of
Consolidated Statement of Earnings line items.
n/m = Percent change is not meaningful.
Abbott Laboratories and Subsidiaries
Consolidated Statement of Earnings
First Half Ended June 30, 2012 and 2011
(in millions, except per share data)
(unaudited)
%
2012 2011 Change
$ $
Net Sales 19,264 18,657 3.3
Cost of products sold 7,362 7,729 (4.8)
Research and development 2,017 1,968 2.5
Acquired in-process and collaborations research and
development 260 273 n/m
Selling, general and
administrative 5,945 5,613 5.9
Total Operating Cost and Expenses 15,584 15,583 --
Operating earnings 3,680 3,074 19.7
Net interest expense 216 239 (9.6)
Net foreign exchange (gain) loss 11 (43) n/m
Other (income) expense, net (63) 135 n/m 1)
Earnings before taxes 3,516 2,743 28.2
Taxes on earnings 549 (63) n/m 2)
$ $
Net Earnings 2,967 2,806 5.7
$ $
Net Earnings Excluding Specified Items, as described below 3,614 3,186 13.4 3)
$ $
Diluted Earnings per Common Share 1.85 1.79 3.9
Diluted Earnings Per Common Share, Excluding Specified Items,
$ $
as described below 2.26 2.03 11.8 3)
Average Number of Common Shares Outstanding Plus Dilutive
Common Stock Options and Awards 1,589 1,562
1) Other (income) expense, net for 2011 includes a charge
of $137 million for the impact of Abbott's change to a
calendar year end for the international operations
that were previously reported on a November 30
year-end. This is treated as a specified item as noted
below.
2) 2011 Taxes on earnings includes a favorable adjustment
to tax expense of $519 million, or $0.33 per share, as
a result of the resolution of various prior years'
international and U.S. tax positions. This favorable
item is classified as a specified item and excluded
from ongoing results, as discussed below.
3) 2012 Net Earnings Excluding Specified Items excludes
after-tax charges of $98 million, or $0.06 per share,
related to expenses associated with the separation
transaction, $222 million, or $0.14 per share, for
acquired in-process research and development related
to the Galapagos collaboration and the Action Pharma
asset acquisition, $50 million, or $0.03 per share,
for a milestone payment related to the Reata
collaboration, $111 million, or $0.07 per share for
litigation and $166 million, or $0.11 per share,
related primarily to restructuring and integration
charges.
2011 Net Earnings Excluding Specified Items excludes
after-tax charges of $142 million, or $0.09 per share,
associated with the acquisition of Solvay
Pharmaceuticals, $107 million, or $0.07 per share, for
restructuring in the pharmaceutical business, $88
million, or $0.05 per share, for previously announced
cost reduction initiatives and other, $137 million, or
$0.09 per share, for the 2009 and 2010 impact of the
change to a calendar year end for international
operations, $273 million, or $0.17 per share, relating
to acquired in-process research and development
related to the Reata and Biotest collaborations, $76
million, or $0.05 per share, for the impairment of an
R&D intangible asset, and $76 million, or $0.05 per
share, for litigation. These items were offset by a
favorable adjustment from the resolution of prior
years' international and U.S. tax positions for $519
million, or $0.33 per share.
n/m = Percent change is not meaningful.
Questions & Answers
Q1) What drove sales growth in the quarter?
A1) Excluding foreign exchange, worldwide sales increased 6.7 percent.
Reported sales increased 2.0 percent, including an unfavorable 4.7 percent
effect of foreign exchange. In emerging markets, sales increased more than 12
percent, excluding foreign exchange, with strong double-digit growth in many
of the key emerging markets across Abbott's businesses.
Worldwide Nutritionals sales increased 8.3 percent in the quarter, excluding
an unfavorable 2.0 percent effect of foreign exchange. U.S. Nutritionals
increased 13.1 percent, with U.S. Pediatric Nutritionals sales growth of 25.3
percent on continued share gains of our infant formula, Similac®, and
continued double-digit growth of PediaSure®. U.S. Adult Nutritionals grew 3.0
percent, driven by strong growth of Ensure® and Glucerna®. Several new
pediatric and adult nutritional products were launched in the second quarter.
International Nutritionals increased 4.5 percent, excluding an unfavorable 3.5
percent effect of foreign exchange, driven by continued growth of both the
pediatric and adult segments, partially offset by the transition to a direct
distribution model in certain markets.
Global sales of Core Laboratory Diagnostics increased 8.6 percent, excluding
an unfavorable 5.3 percent effect of foreign exchange, driven by 15.3 percent
growth in the U.S. due to continued growth of ARCHITECT and PRISM, and 7.2
percent international growth, excluding an unfavorable 6.5 percent effect of
foreign exchange. Point of Care Diagnostics also drove global Diagnostics
sales growth in the quarter.
Worldwide Proprietary Pharmaceuticals sales increased 9.3 percent, excluding
an unfavorable 4.4 percent effect of foreign exchange, driven by strong growth
across a number of key franchises including HUMIRA, AndroGel® and Creon®.
Q2) What is the update on Abbott's planned separation into two leading health
care companies?
A2) In October 2011, Abbott announced plans to separate into two publicly
traded companies, one in diversified medical products and the other in
research-based pharmaceuticals. The diversified medical products company will
consist of Abbott's branded generic pharmaceuticals, devices, diagnostics and
nutritionals businesses, and will retain the Abbott name. The research-based
pharmaceutical company, named AbbVie, will include Abbott's current portfolio
of proprietary pharmaceuticals and biologics.
The transaction is intended to take the form of a tax-free distribution to
Abbott shareholders of a new publicly traded stock for the new pharmaceutical
company. The stock distribution ratio will be determined at a future date. It
is expected that the two companies will each pay a dividend that, when
combined, will at least equal the current Abbott dividend at the time of
separation.
In June, Abbott filed the initial Form 10 for AbbVie, which provided
historical results for AbbVie on a GAAP basis for the past three years, and
for the first quarters of 2012 and 2011. These historical results included an
allocation of certain costs, previously held at the corporate level, to the
business. In addition, senior management assignments for AbbVie were
identified. We expect to file amendments to the Form 10 as more information
becomes available.
We continue to expect the separation to be completed at the end of this year.
Q3) What was the gross margin ratio in the quarter?
A3) The gross margin ratio before and after specified items is shown below
(dollars in millions):
2Q12
Cost of Gross
Products Gross Margin
Sold Margin %
As reported (GAAP) $3,637 $6,170 62.9%
Adjusted for specified items:
Restructuring/integration/other ($42) $42 0.4%
As adjusted $3,595 $6,212 63.3%
The adjusted gross margin ratio was 63.3 percent in the second quarter, an
increase of 310 basis points from the prior year quarter, driven by improved
efficiencies across a number of operating divisions, favorable product mix and
the effect of foreign exchange.
Q4) What drove ongoing SG&A and R&D investment?
A4) Both ongoing SG&A and R&D investment reflect Abbott's continued investment
in programs to drive future growth. Ongoing R&D expense as a percentage of
sales was 9.8 percent, or 10.3 percent on a GAAP basis, reflecting continued
investment in Abbott's pipeline, including programs in vascular devices,
diagnostics, nutritionals, immunology, neuroscience, chronic kidney disease
and hepatitis C.
Q5) What was the tax rate?
A5) The ongoing tax rate this quarter was 15.0 percent, in line with
expectations.
2Q12
Pre-Tax Taxes on Tax
Income Earnings Rate
As reported (GAAP) $2,003 $278 13.9%
Specified items $309 $68 22.0%
Excluding specified items $2,312 $346 15.0%
Q6) How did specified items affect reported results?
A6) Specified items impacted second-quarter results as follows:
2Q12
(dollars in millions, except earnings-per-share) Earnings
Pre-tax After-tax EPS
As reported (GAAP) $2,003 $1,725 $1.08
Adjusted for specified items:
Acquired in-process research and development $110 $71 $0.05
Separation costs $78 $64 $0.04
Restructuring/integration/other $121 $106 $0.06
As adjusted $2,312 $1,966 $1.23
Acquired in-process research and development is related to the acquisition of
AP214 from Action Pharma A/S. Separation costs are expenses related to the
planned separation of Abbott into two leading health care companies.
Restructuring/integration/other is associated with previously announced
restructuring actions and acquisition-related integration costs.
The impact of specified items by Consolidated Statement of Earnings line item
is as follows (dollars in millions):
2Q12
Cost of Acquired Other
Products (Income)/
in-process
Sold R&D R&D SG&A Expense
As reported (GAAP) $3,637 $1,011 $110 $2,945 $8
Adjusted for specified items:
Acquired in-process research and
development -- -- ($110) -- --
Separation costs ($1) -- -- ($77) --
Restructuring/integration/other ($41) ($46) -- ($17) ($17)
As adjusted $3,595 $965 -- $2,851 ($9)
Q7) What are the key areas of focus in Abbott's pipeline?
A7) In the first half of 2012, we made significant progress in advancing both
our pharmaceutical pipeline, which currently includes more than 20 compounds
or new indications in Phase 2 or Phase 3 development, as well as our
diversified medical products pipeline. Following are highlights:
· Hepatitis C
· Abbott's antiviral program is focused on developing treatments for
hepatitis C (HCV), a disease that affects more than 170 million people
worldwide, with approximately 3 to 4 million people newly infected each year.
Abbott's broad-based HCV program includes three mechanisms of action in Phase
2b clinical trials, including protease, polymerase and NS5A inhibitors. Abbott
is evaluating combinations of these compounds, both with and without the
current standard of care, a strategy that has the potential to markedly
transform current treatment practices by shortening therapy duration,
improving tolerability and increasing cure rates.
· Earlier this year, we released positive Phase 2 results from two
interferon-free studies for the treatment of HCV. In the study known as
CO-PILOT, ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks
showed sustained virological response at 12 weeks post treatment (SVR12) in 93
percent and 95 percent of treatment-naive genotype 1 (GT1) patients. In a
separate study, known as PILOT, 91 percent of GT1 infected, treatment-naive
patients taking ABT-450/r and ABT-072 combined with ribavirin administered for
12 weeks, achieved sustained viral response at 24 weeks (SVR24). Larger
Phase 2 clinical trials are ongoing, and we expect to present additional data
later this year.
· Chronic Kidney Disease
· In May, Abbott enhanced its pipeline in renal care with the acquisition
of AP214, an investigational compound in development to prevent acute kidney
injury (AKI) associated with major cardiac surgery in patients at increased
risk. The compound also has further potential in adjacent indications. AP214
is a hormone analogue that targets both systemic inflammation and cellular
death (apoptosis) caused by hypoxia (lack of blood flow) that can occur during
surgery. In September 2011, Action Pharma announced positive Phase 2b top-line
results evaluating the efficacy, safety and tolerability of AP214. Abbott
plans to conduct another Phase 2b study, which is expected to begin later this
year.
· Bardoxolone, an investigational treatment for chronic kidney disease
(CKD), is a first-in-class antioxidant inflammation modulator that activates
Nrf2, a pathway involved in the progression of CKD. A global Phase 3 trial is
currently underway. Abbott's agreement with Reata Pharmaceuticals includes
international rights to bardoxolone, excluding the U.S. and certain Asian
markets.
· Also in development for the treatment of CKD is atrasentan, a compound
discovered by Abbott scientists. A Phase 2b study in patients with diabetic
kidney disease is ongoing with results expected later this year.
· Immunology
· Abbott's scientific experience with HUMIRA serves as a strong
foundation for its continuing research in immunology. We are developing
several additional indications for HUMIRA and have a number of next-generation
programs underway to address various immune-mediated conditions, including
five programs in development for rheumatoid arthritis (RA) alone.
· Abbott recently received approval in Europe for HUMIRA for the
treatment of ulcerative colitis, and in June, we received Positive Opinion in
Europe for HUMIRA in patients with non-radiographic axial spondyloarthritis.
We also initiated two Phase 3 clinical trials to evaluate HUMIRA in patients
with hidradenitis suppurativa, a dermatologic condition for which there are
currently no approved treatments.
· Earlier this year, we announced a global collaboration to develop and
commercialize an oral, next-generation JAK1 inhibitor in Phase 2 development
with the potential to treat RA and other autoimmune diseases. We are also
evaluating a number of other oral programs including an internal JAK1
candidate and a SYK inhibitor. Additionally, in late 2011 we announced plans
to jointly develop and commercialize Reata's portfolio of second-generation
oral antioxidant inflammation modulators, with potential in RA and other
conditions.
· Abbott's proprietary DVD-Ig technology represents an innovative
approach that can target multiple disease-causing antigens with a single
biologic agent. This technology could lead to next-generation biologic
treatments for complex conditions such as cancer or RA, where multiple
pathways are involved in the disease. In 2011, we advanced two DVD-Ig
molecules into Phase 1 clinical trials.
· Abbott's anti-CD4 biologic, BT-061, in development with a partner
company, is currently in Phase 2 clinical trials for RA and psoriasis.
· Oncology
· Abbott's oncology pipeline includes therapies that represent promising,
unique scientific approaches to treating cancer. Abbott is focused on the
development of targeted treatments that inhibit tumor growth and improve
response to common cancer therapies.
· Elotuzumab, an anti-CD37 antibody, is currently in Phase 3 development
with a partner company for multiple myeloma. Abbott is evaluating a number of
promising mechanisms, including work on EGFR, Bcl2, PARP, aurora kinase and
cMET, among others.
· Neuroscience / Pain
· Abbott is conducting innovative research in neuroscience, where it has
developed compounds that target receptors in the brain that help regulate
mood, memory and other neurological functions. Abbott has a number of
compounds in human studies for conditions such as schizophrenia, pain,
Alzheimer's disease, Parkinson's disease and multiple sclerosis (MS).
· Abbott is partnering on the development of a novel, next-generation
antibody, daclizumab, which is currently in Phase 3 clinical trials for MS.
· Additionally, Abbott recently announced positive results from a Phase 3
trial evaluating levodopa-carbidopa intestinal gel (LCIG) for advanced
Parkinson's disease. We expect to submit a U.S. regulatory application for
LCIG this year.
· Women's Health
o Elagolix, a novel, first-in-class oral gonadotropin-releasing hormone
(GnRH), is in development for the treatment of endometriosis-related pain and
fibroids. Abbott and its partner recently initiated a Phase 3 study in
endometriosis and a Phase 2 study in uterine fibroids is underway.
Vision Care
· Abbott expects numerous new products and technology advancements over
the next five years from its cataract, refractive and corneal business units.
In its market-leading LASIK business, Abbott is expanding its proprietary
laser platform into new vision correction applications, including cataract
surgery. Abbott also continues to expand its portfolio of cataract
technologies which includes intraocular lenses (IOLs), phacoemulsification
systems and viscoelastics.
· Abbott recently received U.S. FDA clearance to use Abbott's iFS
Advanced Femtosecond Laser in cataract surgery, giving surgeons the ability to
make precise, bladeless incisions during surgery and customize for each
individual patient. Abbott also expanded its Healon^® family of ophthalmic
viscosurgical devices (OVDs) with the FDA approval of Healon EndoCoat OVD, a
device intended for use as a surgical aid in cataract extraction and IOL
implantation. Additionally, Abbott launched in Europe and Japan the iDesign
Advanced WaveScan Studio aberrometer, a next-generation diagnostic tool for
mapping and analyzing corneal aberrations in the eye.
Vascular Devices
· Abbott has one of the industry's most robust vascular pipelines and is
working on well-staged incremental advances and truly game-changing
technologies that have the ability to restate the market.
· Drug Eluting Stents (DES) - Abbott has several next-generation DES
platforms on the market and in development. Earlier this year, XIENCE PRIME
received approval in Japan, and is now available in all of the major markets
worldwide. Also in development is XIENCE Xpedition®, our next-generation DES
that offers a new catheter for enhanced deliverability, as well as a broader
size matrix. We expect Xpedition to launch in Europe this year and in the
United States in 2013.
· Core Coronary products - Abbott is continuing to expand its position in
the more-than-$2 billion core coronary market. Abbott's next-generation
balloon dilatation catheter, TREK®, is available in the United States, Europe
and Japan, and we plan to introduce additional balloon catheters and
next-generation guide wires over the next few years.
· Bioresorbable Vascular Scaffold (BVS) - Abbott has the most advanced
BVS clinical program in the industry. Absorb^™, the world's first drug-eluting
BVS for the treatment of coronary artery disease, restores blood flow to the
heart by opening a clogged vessel and providing support to the vessel until
the device dissolves, leaving patients with a treated vessel free of a
permanent metallic cage. Absorb is authorized for sale in Europe and is an
investigational device in a number of countries around the world. We recently
presented two-year data demonstrating impressive efficacy and safety results
for Absorb for the treatment of coronary and peripheral artery disease.
· MitraClip - MitraClip^® is a minimally invasive device for the
treatment of select patients with mitral regurgitation (MR), the most common
valve disease in the world. Significant MR affects more than 8 million people
in the United States and Europe, and is four times more prevalent than aortic
stenosis. Abbott's MitraClip system is on the market in Europe and a number of
other countries and is currently under U.S. FDA review.
· Endovascular products - Abbott's endovascular business is led by recent
launches of key products including the Armada peripheral balloon line and the
RX Herculink Elite^® Renal Stent System, and R&D investments in peripheral
artery disease and vessel closure. Earlier this year, we announced U.S. FDA
approval of the Absolute Pro^® Vascular Self-Expanding Stent System for the
treatment of iliac artery disease, a form of peripheral artery disease that
affects the lower extremities.
Molecular Diagnostics
o Earlier this year, Abbott obtained CE Mark in Europe for its rapid,
high-throughput PLEX-ID instrument, along with three assays for use on the
system. PLEX-ID addresses a significant unmet need for rapid detection and
identification of a broad range of microbes that cause infections in patients.
Abbott expects to launch more than 15 new molecular diagnostic products over
the next few years, including several novel oncology, infectious disease and
companion diagnostic assays.
Core Laboratory Diagnostics
· Abbott is focusing on near-term launches of important automation and
informatics solutions to help improve efficiencies in the laboratory. These
important innovations will play a critical role in reducing the time it takes
for a test result to be delivered to the physician to aid in patient
diagnosis. Earlier this month, Abbott announced CE Marking for the ARCHITECT
HbA1c Assay, which detects glycated hemoglobin, used primarily to monitor
long-term diabetes control. Additionally, Abbott expects to launch assays in
the areas of cardiac care, fertility, metabolics and infectious disease, which
will broaden and differentiate its industry-leading menu.
· Future growth for the Core Laboratory Diagnostics business will be
driven by its next-generation blood screening, hematology, and immunochemistry
analyzers, as well as advanced automation and informatics solutions to provide
high-quality results and information, while enhancing laboratory productivity
and reducing costs.
Nutrition
o Abbott is focused on improving six areas through nutrition: immunity,
cognition, lean body mass, inflammation, metabolism and tolerance. In the
first half of 2012, Abbott launched more than 40 new innovations in key
markets around the world, including Similac Stage 1 in India, Similac Total
Comfort in Brazil and Hong Kong, Similac Mom in Taiwan, Glucerna Triple Care
in Vietnam, and Ensure Clear, PediaSure SideKicks Clear and ZonePerfect
Perfectly Simple in the United States. We expect to continue to launch a
number of new products and formulations this year and have more than 30
clinical studies underway to demonstrate proven outcomes with our nutrition
innovation.
Established Pharmaceuticals
o Abbott's large and growing portfolio of more than 500 established
pharmaceuticals consists of trusted, well-known brands that have broad use
throughout the world. Over the next several years, we expect to bring these
medicines to broader patient populations through registrations across multiple
geographies, as well as launches of improved formulations to enhance efficacy
and improve convenience. We continue to expand our presence and launch new
brands, packaging enhancements and formulations.
CONTACT: Financial, John Thomas, +1 (847) 938-2655, or Larry Peepo, +1 (847)
935-6722, or Tina Ventura, +1 (847) 935-9390, or Media, Melissa Brotz, +1
(847) 935-3456, or Scott Stoffel, +1 (847) 936-9502, or Adelle Infante, +1
(847) 938-8745
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR SFLFFAFESEIW -0- Jul/18/2012 11:58 GMT
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement
Rate this Page